Abstract: The present invention relates to a surfactant composition comprising at least one alkylglycoside having the formula CnGm wherein C is an alkyl group; n is the number of carbon atoms in the alkyl group and is 14 to 24; said alkyl group being unbranched or branched, saturated or unsaturated, derivatized or non-derivatized; G is a saccharide residue containing 5 to 6 carbon atoms; and m is a number from 4 to 20. It further also relates to its use and application in detergents, emulsifying agents, wetting agents, anti-aggregation and stabilizing composition and dispersants comprising the same.

Abstract: Provided is a pharmaceutical composition, which comprises 5-{[(3R)-1-acryloylpyrrolidin-3-yl]oxy}-6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-pyrazine-2-carboxamide (hereinafter referred to as “compound A”) or a pharmaceutically acceptable salt thereof, and is stabilized. The pharmaceutical composition comprises compound A or a pharmaceutically acceptable salt thereof, and a pharmaceutical additive having a difference in water activity value of 0.1 or more, and is stabilized.

Abstract: The present application provides a pharmaceutical formulation comprising a folate receptor (FR)-targeting antineoplastic substance or composition, wherein the pharmaceutical formulation is configured for administration by inhalation, wherein the FR-targeting antineoplastic substance or composition is comprised in a nanoparticle and wherein the nanoparticles are comprised in microparticles, and its use in the treatment of a proliferative disease affecting at least part of the respiratory tract. The present application further provides a pharmaceutical formulation comprising an antineoplastic agent and a FR-targeting excipient, for use in the treatment of a proliferative disease affecting at least part of the respiratory tract.

Abstract: The present invention provides a method of intranasal delivery of a pharmaceutical composition, comprising a polysaccharide derivative of insulin protein and a one or more pharmaceutically acceptable excipients, to a subject, wherein the insulin protein is delivered to the brain of the subject through the nasal mucosa.

Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them.

Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

Abstract: Cytisine-linked isoflavonoids, or pharmaceutically acceptable salts thereof or pharmaceutically acceptable compositions thereof, are useful for the treatment of conditions in which cells have a reliance on peroxisomal HSD17B4 to degrade very long chain fatty acids and provide necessary energy for cell proliferation, such as is seen in colorectal cancer and prostate cancer, for example.

Abstract: The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine residues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell delivery system comprising the amphipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy.

Abstract: The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682 having the formula (i) or formula (ii) which further comprises a linker structure X-L1-L2-L3-Y.

Abstract: A conjugate of formula (A): Wherein Y is selected from formulae A1 and A2: Z1 is a C1-3 alkylene group; Z2 is a C1-3 alkylene group; Q is: where QX is such that Q is an amino-acid residue, a dipeptide residue or a tripeptide residue; L is a linker connected to a cell binding agent; CBA is the cell binding agent; and n is an integer between 0 and 48.

Abstract: The technology described herein is directed to agonists of, e.g. Esr2, Dlx5, and/or Egr3, for the inhibition of cancer cells (e.g. squamous carcinoma cancer cells) and the treatment of cancer.

Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilized by sequence modifications and optimized for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilization and translational efficiency of modified mRNA of the invention.

Abstract: Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.

Abstract: Described herein are cell-selective mRNA constructs that can contain a RNA of interest and one or more miRNA targets. The cell-selective mRNA constructs described herein can be used to express an RNA of interest to a cell in a cell-selective manner.

Abstract: Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).

Abstract: A ferumoxytol-based dual-modality imaging probe for long-term stem cell tracking through MRI and early diagnosis of cell apoptosis through simultaneous fluorescence imaging is provided. Specifically, a ferumoxytol-based dual-modality imaging probe is provided with enhanced T2* relaxivity for tracking stem cells through magnetic resonance imaging and detecting apoptotic stem cells through fluorescence imaging.

Abstract: A nanosensor-containing polymer composition for the monitoring of physiological parameters and a method for making the composition are disclosed. The composition includes a nanosensor disposed in a crosslinked, hydrophilic polymer for transdermal application into an intradermal environment. The method involves forming a mixture including nanosensors and a crosslinked polymer precursor, and subjecting the mixture to conditions suitable for crosslinking the polymer precursor to provide a nanosensor-containing crosslinked polymer.

Abstract: Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) or frequency labeled exchange (FLEX) imaging are disclosed. Beta-hydroxycarboxylate and beta-aminocarboxylate derivatives including salicylic acid, salicylates, salicylic acid prodrugs, N-alkyl/aryl/acyl/sulfonyl-anthranilic acid analogs, and any aromatic compound with OH/NH group ortho to the carboxylic acid group are disclosed. Such compounds can be used as general MRI organic contrast agents and produce significantly improved contrast in MR images detectable through CEST or FLEX.

Abstract: The present invention relates to a magnetic resonance structure with a cavity or a reserved space that provides contrast and the additional ability to frequency-shift the spectral signature of the NMR-susceptible nuclei such as water protons by a discrete and controllable characteristic frequency shift that is unique to each MRS design. The invention also relates to nearly uniform solid magnetic resonance T2* contrast agents that have a significantly higher magnetic moment compared to similarly-sized existing MRI contrast agents.

Abstract: Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I): wherein R1 is a moiety including a positron emitter; R2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R1 is a moiety including an adamantyl group.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula; wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, mi-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: The present invention relates to novel pyridinoxy phenylpropanamines, their pharmaceutical compositions and methods of use. In addition, the present invention relates to therapeutic methods that penetrate the blood-brain barrier and regulate the norepinephrine and serotonin transporters (“NET/SERT”).

Abstract: The invention described herein relates to conjugates and compositions for imaging, diagnosing, and/or monitoring diseases using radionuclide-based imaging. In particular, the invention described herein relates to conjugates and compositions for imaging, diagnosing, and/or monitoring diseases using positron emission tomography.

Abstract: The present technology comprises methods for regulating an the immune system, and in particular methods for the regulation of a specific immune response, including the regulation of lymphocyte activity. Methods of the present technology comprise both the negative and positive modulation of CEACAM1 protein function.

Abstract: The invention relates to a garment sanitizing device (1, 31) comprising a housing (2), a chamber (4) within the housing to receive one or more garments (14) to be sanitized. The chamber (4) comprises a bottom wall, a top wall, and opposite first and second sides each extending from the bottom wall to the top wall. The housing contains a fan (6) and one or more heating elements (10). The at least one heating element is configured to directly heat garments within the chamber by radiation, and the fan is configured to convey air via the at least one heating element to heat the air and to convey the heated air through the chamber to additionally heat the garments by the conveyed heated air.

Abstract: Methods and apparatus for sterilization are presented. An apparatus includes a sterilizing cabinet assembly including a cabinet having an access port and a bottom, the bottom configurable to induce a condensate to flow on the bottom to a vent port. The apparatus further includes a door connected to the cabinet, the door moveable between an open position permitting passage through the access port to an interior of the cabinet and a closed position precluding passage through the access port. The apparatus also includes at least one of the cabinet and the door having the vent port, and a filter overlying the vent port and forming a sealed interface with an adjacent portion of the one of the cabinet and the door.

Abstract: An apparatus for sanitizing a stethoscope head. The apparatus includes a housing, a reservoir disposed within the housing for containing the sanitizing fluid, one or more applicator pads mounted on the housing, and a dispensing valve for dispensing the sanitizing fluid from the reservoir onto the applicator pad.

Abstract: Embodiments of the invention relate generally to disinfection and, more particularly, to methods, devices, and systems for disinfection of a space. In one embodiment, the invention provides a disinfecting system comprising: a disinfecting composition; and a device for producing a fog of the disinfecting composition, the fog comprising liquid droplets having diameters between about 0.5 micron and about 20 microns. In some embodiments, the invention includes a dehumidifying device for removing the fog of the disinfecting composition from the space.

Abstract: The present invention disclosed a super dry fog generator comprising a liquid-storage device, an atomization device, an air-blower and a dry separation device with an opening on the top; wherein said dry separation device is above said liquid-storage device and connected with said liquid-storage device; said atomization device is located at the exterior of said liquid-storage device; the two ends of said atomization device are connected with said air-blower and the interior of said dry separation device, respectively; said atomization device is connected with said liquid-storage device, and the liquid entering into the interior of said atomization device is blown into the interior of said dry separation device by said air-blower. The disinfection liquid entering into the atomization device from the liquid-storage device is atomized into small atomized liquid particles by the atomization device, and then the small atomized liquid particles are driven into the dry separation device by said air-blower.

Abstract: The present invention relates to methods and devices for providing microbial control and/or disinfection/remediation of an environment. The methods generally comprise: generating a Purified Hydrogen Peroxide Gas (PHPG) that is substantially free of, e.g., hydration, ozone, plasma species, and/or organic species; and directing the gas comprising primarily PHPG into the environment such that the PHPG acts to provide microbial control and/or disinfection/remediation in the environment, preferably both on surfaces and in the air.

Abstract: A scent presentation method is provided that includes generating a random number, determining a presentation condition based on the generated random number, and presenting a scent through pulse ejection based on the determined presentation condition.

Abstract: A miniature scent generating device includes a scented component, a plurality of granular first materials, and a driving unit. The scented component includes a housing, a chamber located in the housing, a ventilation opening penetrating through the housing to communicate with the chamber, and a vibration unit disposed in the chamber. The first materials are provided in the chamber, and have a first scent. The driving unit is connected to the vibration unit. The vibration unit is controlled by the driving unit to vibrate and produce an airflow of perturbation in the chamber, so as to prompt the first materials to pass through the ventilation opening and discharge out of the chamber to disperse the first scent. The miniature scent generating device has the advantage of unlikely spoiled and readily controlling a release concentration of the scent.

Abstract: Disclosed herein are substrates for cell delivery to target tissues requiring treatment for various diseases that induce cell death, damage or loss of function. The substrates are configured to provide seeded cells, including stem cells, with a structural support that allows interconnection with and transmission of biological signals between the cells and the target tissue.

Abstract: A dental implant and a method for manufacturing same which assure early stability and fixation power of an implant by suppressing early osteolysis after an implant procedure, and allowing better bone coherence of the implant surface during an osteogenic period by controlling the speed of bone remodeling.

Abstract: A method of treating peripheral artery diseases in lower limbs by providing a medical device having an expandable member having a drug coating layer which has a crystalline morphological form including a plurality of crystal particles of a water-insoluble drug regularly arranged and uniformly sized on the surface of the medical device, inserting the medical device in peripheral blood vessels, expanding the expandable member, pressing the drug coating layer to a blood vessel wall such that at least part of the plurality of crystals are transferred to the blood vessel wall, and deflating the expandable member such that a pharmacokinetics profile is presented in which a drug concentration in the blood vessels is kept for the inhibition of smooth muscle cell proliferation in a high drug-concentration period of time, and for the non-inhibition of endothelial cell growth in a later low drug-concentration period of time.

Abstract: A medical device that releases a pharmaceutical agent to a target site is disclosed. The medical device includes a balloon, and a coating on at least a portion of the balloon. The coating includes particles of a pharmaceutical agent. Each particle of the particles of the pharmaceutical agent is at least partially encapsulated in a polymer material. A method of releasing a pharmaceutical agent at a target site is also disclosed. The method includes the steps of providing a device including a balloon, and a coating on at least a portion of the balloon, the coating including particles of a pharmaceutical agent, and each particle of the pharmaceutical agent is at least partially encapsulated in a polymer material; positioning the device to allow the balloon to reach the target site; and inflating the balloon of the device.

Abstract: Compositions of P4HB with high purity have been developed. The compositions are prepared by washing P4HB biomass prior to solvent extraction, and precipitating P4HB from solution. The same solvent is preferably used to wash the P4HB biomass, and as a non-solvent to precipitate the polymer from a P4HB solvent solution. The highly pure P4HB compositions are suitable for preparing implants. The implants may be used for the repair of soft and hard tissues.

Abstract: Provided is a method for producing an antithrombotic coating material in which a high molecular weight polymer can be obtained by a solution polymerization using a radical polymerization initiator. The above-mentioned task is achieved by a method for producing an antithrombotic coating material, including steps of: preparing a methanol solution containing a monomer represented by formula (1): wherein in formula (1), R1, R2, and R3 are the same as those described in the specification, respectively; adding a radical polymerization initiator having a 10-hour half-life temperature of 60° C. or less to the methanol solution to prepare a polymerization reaction liquid; and polymerizing the monomer.

Abstract: A medical waste fluid collection and disposal system includes a medical waste fluid collection cart including first and second fluid collection canisters. A valve assembly selectively communicates with the canisters and a valve drive system controls the valve assembly. A liquid level sensor is positioned within each of the canisters. A cart processor communicates with the liquid level sensors and the valve drive system. A cart drain line communicates with the valve assembly and a receptacle, a cart flushing line communicates with the valve assembly and the receptacle and a cart data line and a cart power line communicate with the cart processor and the cart receptacle. A station includes a drain pump that communicates with a drainage system and a station drain line, a flushing pump that communicates with a source of washing liquid and a station flushing line and a station processor in communication with the drain and flushing pumps. A station data line communicates with the station processor.

Abstract: A method and apparatus are disclosed for providing negative pressure at a wound site. The apparatus includes a suction pump for generating negative pressure, a negative pressure reservoir, a valve element arranged to selectively provide a fluid communication path between the reservoir and the wound site while a negative pressure in the negative pressure reservoir is greater than a threshold negative pressure, to thereby provide a desired negative pressure at the wound site, and wherein in response to a pressure in the negative pressure reservoir decreasing to the threshold negative pressure, the suction pump is operable to re-establish an initial negative pressure in the negative pressure reservoir.

Abstract: Embodiments of the present invention disclose a device for removing adipose tissue with a needle(s), comprising a needle hub that comprises at least one needle that contains between 1-1000 holes around the circumference of the needle barrel which allows passage of adipose tissue and other lipoaspirate, and an adipose tissue collection and purification device comprising a plurality of self-contained syringes wherein each of the syringes comprises an inner syringe included within an outer syringe and wherein a filter is attached inside the outer syringe barrel, the filter having a mesh pore size between 30 micro meters and 1000 micro meters, the device being attached to a needle hub. The present invention further provides a system for closed adipose tissue harvesting, purification, and grafting, comprising an adipose tissue removal component, a collection and purification component, and a grafting component. Methods of using the devices or system are also disclosed.

Abstract: Disclosed herein is a fully implantable artificial heart. The use of flat helical springs to align and reciprocate a bellows structure allows the bellows to pump blood, the multiple solenoids with floating magnetized rods and permanent magnet assemblies held by the flat helical springs provide the power. The artificial heart pumps blood with virtually no friction and no parts to wear out. The use of solenoids advantageously move blood in a gentle, controllable manner.

Abstract: An implantable pump system is provided, suitable for use as a left ventricular assist device (LVAD) system, having an implantable pump, a battery, a controller, and a programmer. The implantable pump includes a flexible membrane coupled to an actuator assembly via a skirt that extends toward the inlet of the pump and curves to guide blood toward the outlet. The actuator assembly is magnetically engagable with electromagnetic coils, so that when the electromagnetic coils are energized, the actuator assembly causes wavelike undulations to propagate along the flexible membrane to propel blood from the inlet, across the skirt, and through the outlet of the implantable pump. The controller may be programmed by a programmer to operate at frequencies and duty cycles that mimic physiologic flow rates and pulsatility while operating in an efficient manner that avoids thrombus formation, hemolysis and/or platelet activation.

Abstract: A blood oxygenator is disclosed comprising a housing, a blood inlet, a blood outlet, a spiral volute, a gas inlet, an oxygenator fiber bundle, and a gas outlet. The housing encloses the fiber bundle and provides the structure for the blood flow path and connectors. The fiber bundle comprises gas-exchange membranes which transfer oxygen to the blood and remove carbon dioxide when the blood flows across the membranes. The spiral volute guides the blood to flow through the fiber bundle. A gas flow chamber receives sweep gas containing oxygen and distributes the sweep gas into the fiber membranes, which gas is then exchanged with the blood being oxygenated.

Abstract: A heat exchanger has a hollow fiber membrane layer comprised of a plurality of hollow fiber membrane conduits each of which has a hollow portion allowing a heat medium to pass therethrough. The conduits are derived by winding a base cord of the hollow fiber membrane onto a cylindrical body. The winding follows a generally helical trajectory around the longitudinal axis of the cylindrical body with a plurality of continuous round trips from the first end to the second end and turning back at each respective end, wherein each round trip completes a number of circumferential revolutions N, wherein N is greater than or equal to one, and wherein N is less than two.

Abstract: A blood processing filter comprises an inlet-side flexible container and an outlet-side flexible container that sandwich a filter element, an inlet port, and an outlet port, the filter further comprising: a flow path securing sheet; a first seal portion; and a second seal portion, wherein the flow path securing sheet includes a pair of ribs disposed opposite to each other with the outlet port interposed therebetween, and a slit formed inside of the pair of ribs, and diffusing openings that are disposed outside of the pair of ribs and continuously open from the ribs to the lateral portions of the first seal portion.

Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.

Abstract: One embodiment relates to a pressure sensor apparatus, including a housing with a flexible member and an aperture configured to receive a fluid. The pressure sensor apparatus further includes a first member disposed on the flexible member, a second member removably coupled to the first member configured to move in response to a pressure of the fluid and a sensor configured to detect the movement of the second member. The pressure sensor apparatus generates a pressure signal for the fluid based on the displacement of the second member.

Abstract: The vaginal cleaning device is a lavage device that is adapted for use in personal hygiene. The lavage device is designed to reduce the risk of irritation caused by the inappropriate handling of the lavage device. This is done by eliminating the need to physically handle the dressing associated with the lavage device. The dressing is a sterile absorbent dressing that is contained within a sterile container. The dressing is removed from the sterile container using a plug and port arrangement that inserts an assumedly non-sterile plug into a port that is formed in the center of the dressing. This arrangement separates by distance the non-sterile plug from the sterile surface of the dressing. The lavage device comprises a handle, a dressing, and a sterile container.